Abstract 1783: Trifluorothymidine incorporation into DNA strongly enforces the potential of TAS-102 and leads to remarkably prolonged survival of cancer patients

• Published in: Cancer research (Chicago, Ill.) Vol. 72; no. 8_Supplement; p. 1783
• Main Authors: Tanaka, Nozomu, Oguchi, Kei, Fujita, Ryoto, Suzuki, Takamasa, Yamamura, Keisuke, Fujioka, Akio, Okabe, Hiroyuki, Noguchi, Kazuharu
• Format: Journal Article
• Language: English
• Published: 15.04.2012

Abstract TAS-102 is a novel oral antitumor agent, consisting of trifluorothymidine (FTD) as the active component and thymidine phosphorylase inhibitor (TPI) which prevents degradation of FTD. In a double-blind randomized phase II study conducted in Japan, TAS-102 significantly improved overall survi...